Coley's toxin revisited: Immunotherapy or plasminogen activator therapy of cancer?

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 3, 2005, Pages 424-427

  Zacharski, L R ^a,b,d   Sukhatme, V P ^c  

^a VA MEDICAL CENTER   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR; TOXIN;

BACTERIUM CULTURE; CANCER; CANCER SURVIVAL; HUMAN; IMMUNITY; IMMUNOTHERAPY; PRIORITY JOURNAL; REVIEW; TUMOR CELL; ARTICLE; BACTERIAL INFECTION; BIOLOGICAL THERAPY; HISTORY; METHODOLOGY; NEOPLASM;

BACTERIAL INFECTIONS; BIOLOGICAL THERAPY; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; IMMUNOTHERAPY; NEOPLASMS; PLASMINOGEN ACTIVATORS;

EID: 23944458657     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01110.x     Document Type: Review

References (53)

1. Bickels J, Kollender Y, Merinsky O, Meller I. Coley's toxin: historical perspective. Israel Med Assoc J 2002; 4: 471-2.
2. Gresser IA. Chekhov MD and Coley's toxin. N Engl J Med 1987; 317: 457.
3. Nauts HC, Fowler GAA, Bogato FH. A review of the influence of bacterial infection and of bacterial products (Coley's toxins) on malignant tumors in man. Acta Med Scand 1953; 145 (Suppl. 276): 5-103.
4. Murray EGD. A synopsis of the history of medical bacteriology. In: Dubos, RJ, ed. Bacterial and Mycotic Infections of Man, 3rd edn. Philadelphia (PA): Lippincott, 1958: 1-13.
5. Burnet M. The history of immunological ideas. Chapter 1. In: Cellular Immunology Bacterial and Mycotic Infections of Man, Cambridge: Cambridge University Press, 1969; 3-20.
6. Rosenberg SA. Principles of cancer management: biologic therapy. In: DeVita, VT Jr, Hellman, S, Rosenberg, SA, eds. Cancer. Principles and Practice of Oncology, 6th edn. Philadelphia (PA): Lippincott Williams & Wilkins, 2001; 307-33.
7. DeVita VT Jr, Hellman S, Rosenberg SA. eds. Cancer. Principles and Practice of Oncology, 6th edn. Philadelphia (PA): Lippincott Williams & Wilkins, 2001.
8. Kufe DW, Pollock RE, Weichselbaum RR, Bast RC Jr, Gansler TS, Holland JF, Frei E III. eds. Cancer Medicine. Hamilton, Ont.: BC Becker Inc., 2003.
9. Christensen EA. Infection and malignant tumours. Acta Pathol Microbiol Scand 1959; 46: 285-95.
10. Christensen EA, Kjems E. Infection and malignant tumours. Acta Pathol Microbiol Scand 1959; 46: 296-304.
11. Collen D. The plasminogen (fibrinolytic) system. Thromb Haemost 1999; 82: 298-304.
12. Huang T-T, Malke H, Ferretti JJ. Heterogeneity of the streptokinase gene in Group A streptococci. Infect Immun 1989; 57: 502-6.
13. Lottenberg R, DesJardin LE, Wang H, Boyle MDP. Streptokinase-producing streptococci grown in human plasma acquire unregulated cell-associated plasmin activity. J Infect Dis 1992; 166: 436-40.
14. Wang H, Lottenberg R, Boyle MD. Analysis of the interaction of group A streptococci with fibrinogen, streptokinase and plasminogen. Microb Pathog 1995; 18: 153-66.
15. Sverdrup B, Blomback M, Borglund E, Hammer H. Blood coagulation and fibrinolytic systems in patients with erysipelas and necrotizing fasciitis. Scand J Infect Dis 1981; 13: 29-36.
16. Hammer H, Blomback M, Sverdrup B, Borglund E. An improved quantitative method for the study of fibrinolysis in the skin as exemplified in patients with leukocytoclastic vasculitis and erysipelas. Acta Derm Venereol 1980; 60: 287-93.
17. Ooe K, Nakada H, Udagawa H, Shimizu Y. Severe pulmonary hemorrhage in patients with serious Group A streptococcal infections: report of two cases. Clin Infect Dis 1999; 28: 1317-19.
18. McCoy HE, Broder CC, Lottenberg R. Streptokinases produced by pathogenic group C streptococci demonstrate species-specific plasminogen activation. J Infect Dis 1991; 164: 515-21.
19. Cliffton EE, Grossi CE. Effect of human plasmin on the toxic effects and growth of blood-borne metastasis of the Brown-Pearce carcinoma and the V2 carcinoma of rabbits. Cancer 1956; 9: 1147-52.
20. Sherry S. Historical developments in fibrinolysis. In: Sawaya R, eds. Fibrinolysis and the Central Nervous System. Philadelphia (PA): Hanley & Belfus, Inc., 1990; 3-13.
21. Seifert KN, McArthur WP, Bleiweis AS, Brady LJ. Characterization of group B streptococcal glyceraldehyde-3-phosphate dehydrogenase. surface localization, enzymatic activity, and protein-protein interactions. Can J Microbiol 2003; 49: 350-6.
22. Courtney HS, Dale JB, Hasty DL. Mapping the fibrinogen-binding domain of serum opacity factor of group a streptococci. Curr Microbiol 2002; 44: 236-40.
23. D'Costa SS, Boyle MD. Interaction of group A streptococci with human plasmin(ogen) under physiological conditions. Methods 2000; 21: 165-77.
24. Rocha CL, Fischetti VA. Identification and characterization of a new protein from Streptococcus pyogenes having homology with fibronectin and fibrinogen binding proteins. Adv Exp Med Biol 1997; 418: 737-9.
25. Costantini V, Zacharski LR, Memoli VA, Kisiel W, Kudryk BJ, Hunt J, Rousseau SM, Stump DC. Fibrinogen deposition without thrombin generation in primary human breast cancer tissue. Cancer Res 1991; 51: 349-53.
26. Costantini V, Zacharski LR. Fibrin and cancer. Thromb Haemost 1993; 69: 406-14.
27. Peuhkurinen KJ, Risteli L, Melkko JT, Linnaluoto M, Jounela A, Risteli J. Thrombolytic therapy with streptokinase stimulates collagen breakdown. Circulation 1991; 83: 1969-75.
28. Tillett WS, Garner RL. The fibrinolytic activity of hemolytic streptococci. J Exp Med 1933; 68: 485-502.
29. Gray HJ. Thromboangiitis: significant findings and theory of etiology (non-specific protein therapy with Coley's erysipelas and prodigiosus toxins). Med Bull Vet Admin 1935; 11: 16-23.
30. Hussein EA, el Dorri A. Intra-arterial streptokinase as adjuvant therapy for complicated Buerger's disease: early trials. Int Surg 1993; 78: 54-8.
31. Zacharski LR, Ornstein DL, Gabazza EC, D'Alessandro-Gabazza CN, Brugarolas A, Schneider J. Treatment of malignancy by activation of the plasminogen system. Semin Thrombos Hemostas 2002; 28: 5-17.
32. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997; 72: 1-22.
33. Zacharski LR, Wojtukiewicz MZ, Costantini V, Ornstein DL, Memoli VA. Pathways of coagulation/fibrinolysis activation in malignancy. Semin Thromb Hemost 1992; 18: 104-16.
34. Zacharski LR, Loynes JR, Ornstein DL, Rigas JR. The plasminogen system and cancer. Biomed Prog 2002; 15: 17-22.
35. Dunbar SD, Ornstein DL, Zacharski LR. Cancer treatment with inhibitors of urokinase-type plasminogen activator and plasmin. Exp Opin Invest Drugs 2000; 9: 2085-92.
36. de Witte JH, Sweep CG, Klijn JG, Grebenschikov N, Peters HA, Look MP, van Tiemoven TH, Heuvel JJ, Bolt-De Vries J, Benraad TJ, Foekens JA. Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer. Br J Cancer 1999; 80: 286-94.
37. de Witte JH, Sweep CG, Klijn JG, Grebenschikov N, Peters HA, Look MP, van Tiemoven TH, Heuvel JJ, van Putten WL, Benraad TJ, Foekens JA. Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients. Br J Cancer 1999; 79: 1190-8.
38. Chappuis PO, Dieterich B, Sciretta V, Lohse C, Bonnefoi H, Remadi S, Sappino AP. Functional evaluation of plasmin formation in primary breast cancer. J Clin Oncol 2001; 19: 2731-8.
39. Mignatti P, Rifkin DB. Plasminogen activators and angiogenesis. Curr Top Microbiol Immunol 1996; 213: 33-50.
40. Mignatti P, Rifkin DB. Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein 1996; 49: 117-37.
41. Kong HL, Crystal RG. Gene therapy strategies for tumor antiangiogenesis. J Natl Cancer Inst 1998; 90: 273-86.
42. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-64.
43. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-85.
44. Browder T, Folkman J, Pirie-Shepherd S. The hemostatic system as a regulator of angiogenesis. J Biol Chem 2000; 275: 1521-4.
45. Weitz JI, Cruickshank MK, Thong B, Leslie B, Levine MN, Ginsberg J, Eckhardt T. Human tissue-type plasminogen activator releases fibrinopeptides A and B from fibrinogen. J Clin Invest 1988; 82: 1700-7.
46. Soff GA. Angiostatin and angiostatin-related proteins. Cancer Metastasis Rev 2000; 19: 97-107.
47. Gately S, Twardowski P, Stack MS, Cundiff DL, Grella D, Castellino FJ, Enghild J, Kwaan HC, Lee F, Kramer RA, Volpert O, Bouck N, Soff GA. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc Natl Acad Sci USA 1997; 94: 10868-72.
48. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-28.
49. Merchan JR, Chan B, Kale S, Schnipper LE, Sukhatme VP. In vitro and in vivo induction of antiangiogenic activity by plasminogen activators and captopril. J Natl Cancer Inst 2003; 95: 388-99.
50. Maskell NA, Gleeson FV. Images in clinical medicine. Effect of intrapleural streptokinase on a loculated malignant pleural effusion. N Engl J Med 2003; 1348: e4.
51. Jerjes-Sanchez C, Ramirez-Rivera A, Elizalde JJ, Delgado R, Cicero R, Ibarra-Perez C, Arroliga AC, Padua A, Portales A, Villareal A, Perez-Romo A. Intrapleural fibrinolysis with streptokinase as an adjunctive treatment in hemothorax and empyema: a multicenter trial. Chest 1996; 109: 1514-19.
52. Davies CW, Traill ZC, Gleeson FV, Davies RJ. Intrapleural streptokinase in the management of malignant multiloculated pleural effusions. Chest 1999; 115: 729-33.
53. Zacharski LR. Malignancy as a solid phase coagulopathy. Implications for the etiology, pathogenesis and treatment of cancer. Semin Thrombos Hemostas 2003; 29: 239-46.